Long-term follow-up of patients with adult-onset subacute sclerosing panencephalitis.
Subacute sclerosing panencephalitis (SSPE) is a rare infectious central nervous system disease with a poor prognosis. Nineteen patients, 18 males and one female, ranging in age from 18 to 22, mean 19.6+/-1.5 years with SSPE were evaluated. We treated 9 patients with oral isoprinosine and 10 patients with alpha-interferon plus oral isoprinosine and followed up for 16 to 160 months. Of the 9 patients treated with oral isoprinosine, 7 (77.7%) died, one stabilized, and one showed progression. Seven (70%) of 10 patients treated with alpha-interferon plus oral isoprinosine died, one showed progression, and stabilization was observed in two patients. Thus, we suggest that isoprinosine alone or in combination with intraventricular interferon did not change the prognosis in long-term follow-up periods.
Eroglu
Erdal
E
GATA Medical Faculty Department of Neurology, Etlik-ANKARA, Turkey. erdale1965@yahoo.com
Gokcil
Zeki
Z
Bek
Semai
S
Ulas
Umit H
UH
Ozdag
Mehmet F
MF
Odabasi
Zeki
Z
D000284:Administration, Oral; D000293:Adolescent; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D007542:Inosine Pranobex / Q000008:administration & dosage*; D016898:Interferon-alpha / Q000008:administration & dosage*; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D008297:Male; D009207:Myoclonus / Q000188:drug therapy / Q000209:etiology; D013344:Subacute Sclerosing Panencephalitis / Q000134:cerebrospinal fluid / Q000150:complications / Q000188:drug therapy*; D016019:Survival Analysis; D055815:Young Adult
D007155:Immunologic Factors; D016898:Interferon-alpha; D007542:Inosine Pranobex